Phospho-CAMK2A/CAMK2D (T286) Antibody

What molecular structures do Phospho-CAMK2A (T286) antibodies recognize?

Phospho-CAMK2A (T286) antibodies specifically recognize the ~50 kDa alpha-CaMKII subunit phosphorylated at the threonine 286 residue. Many of these antibodies will also detect the related ~60 kDa beta-CaMKII subunit phosphorylated at threonine 287 due to sequence homology in this region . This dual recognition capability should be considered when interpreting experimental results in tissues expressing both isoforms.

How can I validate the phospho-specificity of my anti-Phospho-CAMK2A (T286) antibody?

The gold standard for validating phospho-specificity is treating your samples with lambda phosphatase (λ-PPase) prior to immunodetection. As demonstrated in control experiments, treatment with 1200 U of λ-PPase for 30 minutes completely eliminates immunolabeling with the phospho-specific antibody . This control confirms that the antibody is truly recognizing the phosphorylated form rather than the non-phosphorylated protein.

What are the primary research applications for Phospho-CAMK2A (T286) antibodies?

These antibodies are widely employed across multiple techniques including:

• Western blot for quantitative analysis of phosphorylation levels

• Immunohistochemistry for tissue localization studies

• Immunocytochemistry/immunofluorescence for subcellular localization

• Proximity ligation assays for in situ detection of individual phosphorylated proteins

• ELISA for high-throughput quantification

Each application requires specific optimization parameters, including antibody dilution, incubation conditions, and appropriate controls.

How should I prepare brain tissue samples for optimal detection of phosphorylated CAMK2A?

Brain tissue preservation is critical for maintaining phosphorylation states. For optimal results:

• Rapidly extract and flash-freeze tissue in liquid nitrogen

• Use phosphatase inhibitor cocktails in all extraction buffers

• Maintain samples at 4°C during homogenization

• Process samples immediately after thawing to prevent dephosphorylation

• Consider using specialized phospho-preservation fixatives for immunohistochemistry applications

The phosphorylation at T286 can be rapidly lost due to phosphatase activity if these precautions are not observed .

What controls should be included when analyzing CAMK2A phosphorylation via Western blot?

A comprehensive Western blot experiment examining CAMK2A phosphorylation should include:

This control panel allows for reliable quantification and interpretation of phosphorylation changes .

Why is there variability in molecular weight detection between different CAMK2A antibodies?

Observed molecular weight variations (commonly between 50-60 kDa) may stem from:

• Detection of different CaMKII isoforms (alpha: ~50 kDa, beta: ~60 kDa)

• Post-translational modifications affecting protein migration

• Splice variants present in different tissues

• Differences in gel systems and running conditions

When comparing results across studies, it's essential to consider these factors and validate the specific isoform being detected in your experimental system.

How can Proximity Ligation Assay (PLA) be optimized for visualizing individual phosphorylated CAMK2A molecules in situ?

The Proximity Ligation Assay is a powerful technique for visualizing individual phosphorylated proteins in fixed cells. For optimal CAMK2A phosphorylation detection:

• Use a dual-recognition antibody pair: rabbit polyclonal against phospho-T286 (1:1200 dilution) and mouse monoclonal against total CAMK2A (1:50 dilution)

• Ensure high-quality fixation (4% paraformaldehyde for 15 minutes) to preserve phosphorylation state

• Include appropriate permeabilization (0.1% Triton X-100, 10 minutes)

• Employ stringent blocking (5% BSA, 1 hour) to minimize background signal

• Analyze images with specialized software like BlobFinder to quantify individual phosphorylation events

Each red dot in the resulting images represents a single phosphorylated CAMK2A molecule, allowing for quantitative spatial analysis of phosphorylation patterns.

What strategies can differentiate between CAMK2A phosphorylation at T286 versus T305/T306 sites?

Differentiating between these regulatory phosphorylation sites is crucial as they have opposing effects on kinase activity. Research approaches include:

• Using site-specific antibodies in parallel experiments (anti-phospho-T286 vs. anti-phospho-T305/306)

• Employing phosphatase treatments with different specificities

• Using site-specific mutants (T286A, T305A/T306A) as controls

• Sequential immunoprecipitation with one phospho-antibody followed by blotting with the other

• Mass spectrometry analysis for definitive site mapping and quantification

The ratio between T286 and T305/306 phosphorylation provides insight into the activation state of the kinase and its potential for downstream signaling.

How can phospho-CAMK2A antibodies be leveraged for studying the spatial dynamics of CAMK2A activation in dendritic spines?

Advanced imaging approaches using phospho-specific antibodies can reveal compartmentalized activation of CAMK2A:

• Super-resolution microscopy (STORM, PALM) with phospho-T286 antibodies can visualize nanoscale clustering of activated CAMK2A

• FRET-based reporters combined with immunocytochemistry can correlate CAMK2A activity with structural changes

• Time-resolved fixation after stimulation can capture the temporal dynamics of phosphorylation

• Proximity ligation assays can detect interaction between phospho-CAMK2A and specific substrates

• Correlative light and electron microscopy can link activation to ultrastructural features

These approaches have revealed that CAMK2A phosphorylation is highly compartmentalized and dynamically regulated within dendritic spines during synaptic plasticity.

Why might I observe discrepancies between total CAMK2A and phospho-T286 CAMK2A signals?

Several factors can contribute to apparent discrepancies:

• Epitope masking due to protein-protein interactions affecting antibody accessibility

• Different antibody affinities between phospho-specific and total antibodies

• Non-linear relationship between signal intensity and protein quantity

• Rapid dephosphorylation during sample processing

• Differential extraction efficiency of phosphorylated versus non-phosphorylated forms

To address these issues, perform parallel experiments with phosphatase treatment, use multiple antibodies targeting different epitopes, and validate findings with complementary techniques .

What are common pitfalls when quantifying CAMK2A phosphorylation in tissue sections?

Accurate quantification of phospho-CAMK2A in immunohistochemistry faces several challenges:

• Phosphorylation loss during fixation and processing (use rapid fixation and phosphatase inhibitors)

• Regional variations in antibody penetration (use consistent section thickness)

• Non-specific binding in certain brain regions (validate with phosphatase-treated controls)

• Variability in staining intensity between experiments (include standard samples across batches)

• Automated quantification challenges due to subcellular localization (develop appropriate segmentation algorithms)

Standardized protocols with appropriate controls are essential for meaningful comparisons between experimental conditions.

How can I distinguish between specific and non-specific bands when detecting phospho-CAMK2A via Western blot?

Verifying band specificity is crucial for accurate interpretation:

• Compare molecular weights with predicted values (alpha-CAMK2A: ~50 kDa, beta-CAMK2A: ~60 kDa)

• Perform lambda phosphatase treatment to identify phospho-dependent bands

• Use knockout or knockdown samples as negative controls

• Pre-absorb antibody with immunizing phosphopeptide to block specific binding

• Compare patterns across multiple phospho-specific antibodies

A comprehensive validation approach ensures confident identification of specific phospho-CAMK2A signals among potential cross-reactive bands.

How are phospho-CAMK2A antibodies being used to investigate disease-associated alterations in CAMK2A signaling?

Phospho-specific antibodies are powerful tools for revealing disease-related dysregulation:

• Neurodegenerative disorders: Altered T286 phosphorylation in Alzheimer's disease models

• Cardiac pathologies: Abnormal CAMK2A activation patterns in heart failure

• Ischemic conditions: Excitotoxic hyperphosphorylation following oxygen-glucose deprivation

• Psychiatric disorders: Disrupted CAMK2A signaling in schizophrenia and autism models

• Cancer biology: Aberrant CAMK2A activation in certain tumor types

These investigations typically employ multiple phospho-specific antibodies to develop a comprehensive profile of kinase dysregulation in pathological states.

What are the considerations when adapting phospho-CAMK2A detection for high-throughput screening applications?

Scaling up phospho-CAMK2A detection for drug discovery or large-scale studies requires:

• Optimization of ELISA-based detection methods with phospho-specific antibodies

• Development of cell-based reporter assays that correlate with T286 phosphorylation

• Automated image analysis workflows for immunofluorescence quantification

• Validation of surrogate markers that reliably indicate CAMK2A activation status

• Standardization protocols to ensure consistency across experimental batches

These adaptations enable screening of compound libraries for modulators of CAMK2A signaling with potential therapeutic applications.

How can phospho-specific antibodies be combined with mass spectrometry for comprehensive analysis of the CAMK2A phosphoproteome?

Integrative approaches combining antibody-based methods with mass spectrometry offer powerful insights:

• Immunoprecipitation with phospho-T286 antibodies followed by MS/MS analysis identifies interacting partners specific to the activated state

• Parallel reaction monitoring (PRM) using synthetic phosphopeptide standards enables absolute quantification of phosphorylation stoichiometry

• Combined phospho-enrichment strategies (antibody-based and chemical) increase coverage of low-abundance phosphorylation sites

• Spatial mass spectrometry following immunohistochemical validation reveals region-specific phosphorylation patterns

• Correlation of antibody-based quantification with MS-based measurements provides cross-validation of phosphorylation dynamics

These approaches have revealed complex, multisite phosphorylation patterns that regulate CAMK2A function beyond the well-characterized T286 site.